PMID- 23031319
OWN - NLM
STAT- MEDLINE
DCOM- 20130325
LR  - 20211021
IS  - 1746-6148 (Electronic)
IS  - 1746-6148 (Linking)
VI  - 8
DP  - 2012 Oct 3
TI  - Comparison of the efficacy of autogenous inactivated Porcine Reproductive and 
      Respiratory Syndrome Virus (PRRSV) vaccines with that of commercial vaccines 
      against homologous and heterologous challenges.
PG  - 182
LID - 10.1186/1746-6148-8-182 [doi]
AB  - BACKGROUND: The porcine reproductive and respiratory syndrome virus (PRRSV) is a 
      rapidly evolving pathogen of swine. At present, there is a high demand for safe 
      and more effective vaccines that can be adapted regularly to emerging virus 
      variants. A recent study showed that, by the use of a controlled inactivation 
      procedure, an experimental BEI-inactivated PRRSV vaccine can be developed that 
      offers partial protection against homologous challenge with the prototype strain 
      LV. At present, it is however not known if this vaccine can be adapted to 
      currently circulating virus variants. In this study, two recent PRRSV field 
      isolates (07 V063 and 08 V194) were used for BEI-inactivated vaccine production. 
      The main objective of this study was to assess the efficacy of these experimental 
      BEI-inactivated vaccines against homologous and heterologous challenge and to 
      compare it with an experimental LV-based BEI-inactivated vaccine and commercial 
      inactivated and attenuated vaccines. In addition, the induction of challenge 
      virus-specific (neutralizing) antibodies by the different vaccines was assessed. 
      RESULTS: In a first experiment (challenge with 07 V063), vaccination with the 
      experimental homologous (07 V063) inactivated vaccine shortened the viremic phase 
      upon challenge with approximately 2 weeks compared to the mock-vaccinated control 
      group. Vaccination with the commercial attenuated vaccines reduced the duration 
      of viremia with approximately one week compared to the mock-vaccinated control 
      group. In contrast, the experimental heterologous (LV) inactivated vaccine and 
      the commercial inactivated vaccine did not influence viremia. Interestingly, both 
      the homologous and the heterologous experimental inactivated vaccine induced 07 
      V063-specific neutralizing antibodies upon vaccination, while the commercial 
      inactivated and attenuated vaccines failed to do so.In the second experiment 
      (challenge with 08 V194), use of the experimental homologous (08 V194) 
      inactivated vaccine shortened viremia upon challenge with approximately 3 weeks 
      compared to the mock-vaccinated control group. Similar results were obtained with 
      the commercial attenuated vaccine. The experimental heterologous (07 V063 and LV) 
      inactivated vaccines did not significantly alter viremia. In this experiment, 08 
      V194-specific neutralizing antibodies were induced by the experimental homologous 
      and heterologous inactivated vaccines and a faster appearance post challenge was 
      observed with the commercial attenuated vaccine. CONCLUSIONS: The experimental 
      homologous inactivated vaccines significantly shortened viremia upon challenge. 
      Despite the concerns regarding the efficacy of the commercial attenuated vaccines 
      used on the farms where the field isolates were obtained, use of commercial 
      attenuated vaccines clearly shortened the viremic phase upon challenge. In 
      contrast, the experimental heterologous inactivated vaccines and the commercial 
      inactivated vaccine had no or only a limited influence on viremia. The 
      observation that homologous BEI-inactivated vaccines can provide a more or less 
      standardized, predictable degree of protection against a specific virus variant 
      suggests that such vaccines may prove useful in case virus variants emerge that 
      escape the immunity induced by the attenuated vaccines.
FAU - Geldhof, Marc F
AU  - Geldhof MF
AD  - Laboratory of Virology, Faculty of Veterinary Medicine, Ghent University, 
      Salisburylaan 133, Merelbeke, 9820, Belgium. marc.geldhof@UGent.be
FAU - Vanhee, Merijn
AU  - Vanhee M
FAU - Van Breedam, Wander
AU  - Van Breedam W
FAU - Van Doorsselaere, Jan
AU  - Van Doorsselaere J
FAU - Karniychuk, Uladzimir U
AU  - Karniychuk UU
FAU - Nauwynck, Hans J
AU  - Nauwynck HJ
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20121003
PL  - England
TA  - BMC Vet Res
JT  - BMC veterinary research
JID - 101249759
RN  - 0 (Antibodies, Neutralizing)
RN  - 0 (Antibodies, Viral)
RN  - 0 (Vaccines, Inactivated)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - Animals
MH  - Antibodies, Neutralizing
MH  - Antibodies, Viral
MH  - Cell Line
MH  - Genome, Viral
MH  - Mutation
MH  - Phylogeny
MH  - Porcine Reproductive and Respiratory Syndrome/*prevention & control
MH  - Porcine respiratory and reproductive syndrome virus/genetics/*immunology
MH  - Swine
MH  - Vaccines, Inactivated/immunology
MH  - Viral Vaccines/*immunology
MH  - Viremia
PMC - PMC3514241
EDAT- 2012/10/04 06:00
MHDA- 2013/03/26 06:00
PMCR- 2012/10/03
CRDT- 2012/10/04 06:00
PHST- 2012/04/11 00:00 [received]
PHST- 2012/09/23 00:00 [accepted]
PHST- 2012/10/04 06:00 [entrez]
PHST- 2012/10/04 06:00 [pubmed]
PHST- 2013/03/26 06:00 [medline]
PHST- 2012/10/03 00:00 [pmc-release]
AID - 1746-6148-8-182 [pii]
AID - 10.1186/1746-6148-8-182 [doi]
PST - epublish
SO  - BMC Vet Res. 2012 Oct 3;8:182. doi: 10.1186/1746-6148-8-182.